Invasive infection due toTrichosporon cutaneum in patients with hematologic malignancies

Kataoka-Nishimura, Shigeko; Akiyama, Hideki; Saku, Kazue; Kashiwa, Machiko; Mori, Shinichiro; Tanikawa, S; Sakamaki, Hisashi; Onozawa, Y

doi:10.1002/(sici)1097-0142(19980201)82:3<484::aid-cncr9>3.0.co;2-p

Cited by 26 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For comparison analysis, the cases were clustered according to the main underlying disease, e.g., homeopathy ( n = 79; Grauer et al, 1994 ; Higgins et al, 1994 ; Hsiao et al, 1994 ; Nasu et al, 1994 ; Hung et al, 1995 ; Spánik et al, 1995 ; Itoh et al, 1996 ; Fanci et al, 1997 ; Kataoka-Nishimura et al, 1998 ; Sklair-Levy et al, 1998 ; Krcmery et al, 1999 ; Takamura et al, 1999 ; Erer et al, 2000 ; Kim et al, 2001 ; Moretti-Branchini et al, 2001 ; Fournier et al, 2002 ; Hadley et al, 2002 ; Meyer et al, 2002 ; Chang et al, 2003 ; Marty et al, 2003 ; Bassetti et al, 2004 ; Chowdhary et al, 2004 ; Viscomi et al, 2004 ; Antachopoulos et al, 2005 ; Chan-Tack, 2005 ; Akagi et al, 2006 ; Ghiasian et al, 2006 ; Kendirli et al, 2006 ; Koyanagi et al, 2006 ; Matsue et al, 2006 ; Meguro-Hashimoto et al, 2006 ; Rodrigues et al, 2006 ; Hara et al, 2007 ; Miura et al, 2007 ; Rieger et al, 2007 ; Bayramoglu et al, 2008 ; Hosoki et al, 2008 ; Thibeault et al, 2008 ; Tsuji et al, 2008 ; Fekkar et al, 2009 ; Walia et al, 2009 ; Gabriel et al, 2011 ; Kudo et al, 2011 ; Hosokawa et al, 2012 ; Menezes et al, 2012 ; Chen et al, 2014 ; Issarachaikul et al, 2014 ; Karapinar et al, 2014 ; Capoor et al, 2015 ; Odero et al, 2015 ; Pérard et al, 2015 ; Tanyildiz et al, 2015 ), other immunodeficiency conditions ( n = 41; Canales et al, 1998 ; Lascaux et al, 1998 ; Anuradha et al, 2000 ; Piwoz et al,…”

Section: Resultsunclassified

Invasive Trichosporon Infection: a Systematic Review on a Re-emerging Fungal Pathogen

2016

View full text Add to dashboard Cite

Objectives: This review aimed to better depict the clinical features and address the issue of therapeutic management of Trichosporon deep-seated infections.Methods: We comprehensively reviewed the cases of invasive Trichosporon infection reported in the literature from 1994 (date of taxonomic modification) to 2015. Data from antifungal susceptibility testing (AST) studies were also analyzed.Results: Two hundred and three cases were retained and split into four groups: homeopathy (n = 79), other immunodeficiency conditions (n = 41), miscellaneous (n = 58) and newborns (n = 25). Trichosporon asahii was the main causative species (46.7%) and may exhibit cross-resistance to different antifungal classes. The unfavorable outcome rate was at 44.3%. By multivariate analysis, breakthrough infection (OR 2.45) was associated with unfavorable outcome, whilst the use of an azole-based therapy improved the prognosis (OR 0.16). Voriconazole-based treatment was associated with favorable outcome in hematological patients (73.6 vs. 41.8%; p = 0.016). Compiled data from AST demonstrated that (i) T. asahii exhibits the highest MICs to amphotericin B and (ii) voriconazole has the best in vitro efficacy against clinical isolates of Trichosporon spp.Conclusions: Trichosporon infection is not only restricted to hematological patients. Analysis of compiled data from AST and clinical outcome support the use of voriconazole as first line therapy.

show abstract

Section: Resultsunclassified

Invasive Trichosporon Infection: a Systematic Review on a Re-emerging Fungal Pathogen

2016

View full text Add to dashboard Cite

show abstract

“…Invasive infections due to Trichosporon are rare, but can be fatal to immuno-compromised patients, and have been observed with growing frequency. 11 Butenafine (1a) and Terbinafine (2a) (Fig. 1) are well established antimycotic agents used among others in topical treatment of dermatocytes invading skin and nails.…”

Section: Introductionmentioning

confidence: 99%

Chiral derivatives of Butenafine and Terbinafine: synthesis and antifungal activity

et al. 2009

View full text Add to dashboard Cite

“…Trichosporon asahii fungemia has been described in organ transplant recipients, patients with HIV infection, burn patients, individuals with end-stage renal disease on hemodialysis, and recipients of prosthetic heart valves (1). However, the overwhelming majority of cases occur in patients with leukemia or lymphomas who have developed profound granulocytopenia (2). Fewer cases have been reported in patients with solid malignancies, and the majority of these individuals also have severe depletion of neutrophils as the most prominent risk factor (3).…”

mentioning

confidence: 99%

<i>Trichosporon asahii</i> Fungemia in a Patient with Non-Hematological Malignancy

Karabay,

Madariaga,

Kocoglu

et al. 2006

Jpn J Infect Dis

View full text Add to dashboard Cite

Trichosporon fungemia is usually seen in neutropenic patients with underlying hematological malignancies. In this report we describe a fatal case of Trichosporon asahii fungemia in a non-neutropenic patient with a non-hematological malignancy. For 1 week the patient exhibited hematuria, weakness, easy fatigability and headaches. At admission she had anemia, renal failure and evidence of right hydronephrosis and bladder wall masses as detected by CT scan. She did not have a history of tobacco abuse, contact with urinary carcinogens or Schistosoma infestation; her clinical picture was suggestive of bladder cancer. After some investigations the patient underwent radical cystectomy and ileal conduit surgery because of transitional cell carcinoma in the urinary bladder. After an initial uneventful improvement postoperatively the patient deteriorated and died of septic shock despite all reanimation efforts and antibiotherapy including fluconazole. The blood culture obtained 4 days before the patient died revealed T. asahii, which was isolated on the day she died and found to be resistant to fluconazole and caspofungin. This report suggests that clinicians remain aware that T. asahii fungemia may develop in clinically deteriorated patients even if they do not have a hematological malignancy.

show abstract

Invasive infection due toTrichosporon cutaneum in patients with hematologic malignancies

Abstract: More effective antifungal agents are required for the treatment of infections with this organism.

Cited by 26 publications

References 11 publications

Invasive Trichosporon Infection: a Systematic Review on a Re-emerging Fungal Pathogen

Invasive Trichosporon Infection: a Systematic Review on a Re-emerging Fungal Pathogen

Chiral derivatives of Butenafine and Terbinafine: synthesis and antifungal activity

<i>Trichosporon asahii</i> Fungemia in a Patient with Non-Hematological Malignancy

Contact Info

Product

Resources

About